207 related articles for article (PubMed ID: 37419133)
21. Patients with liver cirrhosis show worse survival if decompensation occurs later during course of disease than at diagnosis.
Nilsson E; Anderson H; Sargenti K; Lindgren S; Prytz H
Scand J Gastroenterol; 2018 Apr; 53(4):475-481. PubMed ID: 29513096
[TBL] [Abstract][Full Text] [Related]
22. Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis.
Navadurong H; Thanapirom K; Wejnaruemarn S; Prasoppokakorn T; Chaiteerakij R; Komolmit P; Treeprasertsuk S
World J Gastroenterol; 2023 Aug; 29(32):4873-4882. PubMed ID: 37701131
[TBL] [Abstract][Full Text] [Related]
23. Role of magnetic resonance elastography in compensated and decompensated liver disease.
Asrani SK; Talwalkar JA; Kamath PS; Shah VH; Saracino G; Jennings L; Gross JB; Venkatesh S; Ehman RL
J Hepatol; 2014 May; 60(5):934-9. PubMed ID: 24362072
[TBL] [Abstract][Full Text] [Related]
24. Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B.
Lee HW; Yip TC; Tse YK; Wong GL; Kim BK; Kim SU; Park JY; Kim DY; Chan HL; Ahn SH; Wong VW
Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1950-1958.e7. PubMed ID: 32889148
[TBL] [Abstract][Full Text] [Related]
25. MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses.
Noureddin N; Ajmera V; Bergstrom J; Bettencourt R; Huang DQ; Siddiqi H; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Loomba R
Aliment Pharmacol Ther; 2023 Nov; 58(9):856-865. PubMed ID: 37694993
[TBL] [Abstract][Full Text] [Related]
26. Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis.
Das K; Das K; Datta S; Pal S; Hembram JR; Dhali GK; Santra A; Chowdhury A
Liver Int; 2010 Aug; 30(7):1033-42. PubMed ID: 20492502
[TBL] [Abstract][Full Text] [Related]
27. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis.
Orman ES; Roberts A; Ghabril M; Nephew L; Desai AP; Patidar K; Chalasani N
JAMA Netw Open; 2019 Jun; 2(6):e196412. PubMed ID: 31251379
[TBL] [Abstract][Full Text] [Related]
28. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
29. Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis.
Sharpton SR; Oh TG; Madamba E; Wang C; Yu RT; Atkins AR; Huan T; Downes M; Evans RM; Loomba R
Aliment Pharmacol Ther; 2022 Nov; 56(10):1475-1485. PubMed ID: 36164267
[TBL] [Abstract][Full Text] [Related]
30. Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites.
Tan HK; Teng MLP; Soh AYS; Cheo SHY; Fook-Chong S; Goh GBB; Tan CK; Wong GW; Lee GH; Chang JPE
Am J Gastroenterol; 2021 Jul; 116(7):1437-1446. PubMed ID: 33834737
[TBL] [Abstract][Full Text] [Related]
31. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
[TBL] [Abstract][Full Text] [Related]
32. Alpha-1-Antitrypsin Pi*MZ variant increases risk of developing hepatic events in nonalcoholic fatty liver disease patients
Murali AR; Prakash S; Sanchez AJ
Clin Res Hepatol Gastroenterol; 2023 Feb; 47(2):102066. PubMed ID: 36509354
[TBL] [Abstract][Full Text] [Related]
33. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
[TBL] [Abstract][Full Text] [Related]
34. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
Calzadilla-Bertot L; Vilar-Gomez E; Wong VW; Romero-Gomez M; Aller-de la Fuente R; Wong GL; Castellanos M; Eslam M; Desai AP; Jeffrey GP; George J; Chalasani N; Adams LA
Hepatology; 2021 Jun; 73(6):2238-2250. PubMed ID: 32978796
[TBL] [Abstract][Full Text] [Related]
35. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
36. MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death.
Truong E; Gornbein JA; Yang JD; Noureddin N; Harrison SA; Alkhouri N; Noureddin M
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2570-2577.e1. PubMed ID: 36813013
[TBL] [Abstract][Full Text] [Related]
37. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
[TBL] [Abstract][Full Text] [Related]
38. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
Lin H; Lee HW; Yip TC; Tsochatzis E; Petta S; Bugianesi E; Yoneda M; Zheng MH; Hagström H; Boursier J; Calleja JL; Goh GB; Chan WK; Gallego-Durán R; Sanyal AJ; de Lédinghen V; Newsome PN; Fan JG; Castéra L; Lai M; Harrison SA; Fournier-Poizat C; Wong GL; Pennisi G; Armandi A; Nakajima A; Liu WY; Shang Y; de Saint-Loup M; Llop E; Teh KK; Lara-Romero C; Asgharpour A; Mahgoub S; Chan MS; Canivet CM; Romero-Gomez M; Kim SU; Wong VW;
JAMA; 2024 Apr; 331(15):1287-1297. PubMed ID: 38512249
[TBL] [Abstract][Full Text] [Related]
39. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
40. Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia.
Seko Y; Kawanaka M; Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Yamamura S; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Okanoue T; Itoh Y; Nakajima A;
J Gastroenterol Hepatol; 2022 Dec; 37(12):2313-2320. PubMed ID: 36198983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
